Exelixis Inc (EXEL) 1.91 $EXEL
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9
Business Wire - Mon Sep 08, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 8-10 in New York. The Exelixis presentation is scheduled for 11:45 a.m. EDT/8:45 a.m. PDT tomorrow, Tuesday, September 9, 2014.
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Market Maker Surveillance Report. EXEL, BP, SIRI, IGT, GFIG, XRX, Highest Net Sell Volume and Negative Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:16AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Exelixis Inc (NASDAQ:EXEL), BP PLC (NYSE:BP), Sirius XM Radio Inc (NASDAQ:SIRI), International Game Technology (NYSE:IGT), GFI Group Inc (NYSE:GFIG), Xerox Corp (NYSE:XRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Surveillance Report. EPGL, EXEL, IG, T, INTC, GFI, Highest Net Sell Volume and Negative Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Exelixis Inc (NASDAQ:EXEL), IGI Laboratories Inc (NYSE:IG), AT&T Inc (NYSE:T), INTEL CORPORATION (NASDAQ:INTC), Gold Fields Ltd (NYSE:GFI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Surveillance Report. ASTM, EXEL, RSH, CONN, AYSI, SGOC, Losing Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Aastrom Biosciences Inc (NASDAQ:ASTM), Exelixis Inc (NASDAQ:EXEL), RadioShack Corp (NYSE:RSH), CONN'S, INC. (NASDAQ:CONN), ALLOY STEEL INTERNATIONAL (OTC:AYSI), SOLOMON GOLD CORP (NASDAQ:SGOC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Most active Nasdaq-traded stocks
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 9:40AM CDT
Exelixis (EXEL) shares nosedived over 55% on Sep 2 following the announcement that cabozantinib failed to meet the primary endpoint in a phse III study.
Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 8:38AM CDT
Exelixis (EXEL) Enters Oversold Territory
Downgrade Alert for Exelixis (EXEL)
Comtex SmarTrend(R) - Wed Sep 03, 6:59AM CDT
Exelixis (NASDAQ:EXEL) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $1.85 on volume of 43.2 million shares, above average daily volume of 3.2 million. Exelixis, Inc. is involved in comparative genomics and model system genetics. The Company's technologies focus on the identification and validation of novel screening targets and proteins and their function for the pharmaceutical, diagnostic, agricultural, and animal health industries. Exelixis' areas of research include CNS, inflammation, oncology, and metabolic disease.
Why Exelixis Inc. Stock Plunged
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:53PM CDT
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What: Shares of Exelixis , a biopharmaceutical company focused on developing...
Exelixis Down 51.2%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Tue Sep 02, 10:07AM CDT
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 51.2% to $2.02 on 7.2x average daily volume. Exelixis has traded 23.8 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-51.2% to the Dow's 0.1%) and underperformed the S&P 500 (-51.2% to the S&P's 0.1%) during today's trading.
Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today
at The Street - Tue Sep 02, 9:01AM CDT
Shares of Exelixis (EXEL) plummeted in morning trading Tuesday after the drug developer announced cabozantinib did not prolong survival in subjects with advanced prostate cancer in a Phase III trial.
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - Tue Sep 02, 8:33AM CDT
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Ahead of the Bell: Exelixis shares tumble
By The Associated Press - AP - Tue Sep 02, 8:10AM CDT
Shares of Exelixis Inc. shed more than half their value Tuesday before markets opened and a day after the drug developer said its potential treatment for an advanced form of prostate cancer fell short when compared with another drug in late-stage research.
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 6:15AM CDT
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Sep 01, 5:00PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone. The median OS for the cabozantinib arm of the trial was 11.0 months versus 9.8 months for the prednisone arm (hazard ratio 0.90; 95% confidence interval 0.76 - 1.06; p value 0.212).
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9
Business Wire - Mon Sep 08, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 8-10 in New York. The Exelixis presentation is scheduled for 11:45 a.m. EDT/8:45 a.m. PDT tomorrow, Tuesday, September 9, 2014.
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Market Maker Surveillance Report. EXEL, BP, SIRI, IGT, GFIG, XRX, Highest Net Sell Volume and Negative Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:16AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Exelixis Inc (NASDAQ:EXEL), BP PLC (NYSE:BP), Sirius XM Radio Inc (NASDAQ:SIRI), International Game Technology (NYSE:IGT), GFI Group Inc (NYSE:GFIG), Xerox Corp (NYSE:XRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Surveillance Report. EPGL, EXEL, IG, T, INTC, GFI, Highest Net Sell Volume and Negative Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Exelixis Inc (NASDAQ:EXEL), IGI Laboratories Inc (NYSE:IG), AT&T Inc (NYSE:T), INTEL CORPORATION (NASDAQ:INTC), Gold Fields Ltd (NYSE:GFI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Surveillance Report. ASTM, EXEL, RSH, CONN, AYSI, SGOC, Losing Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Aastrom Biosciences Inc (NASDAQ:ASTM), Exelixis Inc (NASDAQ:EXEL), RadioShack Corp (NYSE:RSH), CONN'S, INC. (NASDAQ:CONN), ALLOY STEEL INTERNATIONAL (OTC:AYSI), SOLOMON GOLD CORP (NASDAQ:SGOC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Most active Nasdaq-traded stocks
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 9:40AM CDT
Exelixis (EXEL) shares nosedived over 55% on Sep 2 following the announcement that cabozantinib failed to meet the primary endpoint in a phse III study.
Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 8:38AM CDT
Exelixis (EXEL) Enters Oversold Territory
Downgrade Alert for Exelixis (EXEL)
Comtex SmarTrend(R) - Wed Sep 03, 6:59AM CDT
Exelixis (NASDAQ:EXEL) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $1.85 on volume of 43.2 million shares, above average daily volume of 3.2 million. Exelixis, Inc. is involved in comparative genomics and model system genetics. The Company's technologies focus on the identification and validation of novel screening targets and proteins and their function for the pharmaceutical, diagnostic, agricultural, and animal health industries. Exelixis' areas of research include CNS, inflammation, oncology, and metabolic disease.
Why Exelixis Inc. Stock Plunged
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:53PM CDT
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What: Shares of Exelixis , a biopharmaceutical company focused on developing...
Exelixis Down 51.2%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Tue Sep 02, 10:07AM CDT
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 51.2% to $2.02 on 7.2x average daily volume. Exelixis has traded 23.8 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-51.2% to the Dow's 0.1%) and underperformed the S&P 500 (-51.2% to the S&P's 0.1%) during today's trading.
Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today
at The Street - Tue Sep 02, 9:01AM CDT
Shares of Exelixis (EXEL) plummeted in morning trading Tuesday after the drug developer announced cabozantinib did not prolong survival in subjects with advanced prostate cancer in a Phase III trial.
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - Tue Sep 02, 8:33AM CDT
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Ahead of the Bell: Exelixis shares tumble
By The Associated Press - AP - Tue Sep 02, 8:10AM CDT
Shares of Exelixis Inc. shed more than half their value Tuesday before markets opened and a day after the drug developer said its potential treatment for an advanced form of prostate cancer fell short when compared with another drug in late-stage research.
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 6:15AM CDT
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Sep 01, 5:00PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone. The median OS for the cabozantinib arm of the trial was 11.0 months versus 9.8 months for the prednisone arm (hazard ratio 0.90; 95% confidence interval 0.76 - 1.06; p value 0.212).
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
